Validation of dried blood spot sampling in therapeutic drug monitoring of nilotinib

Validation of dried blood spot sampling in therapeutic drug monitoring of nilotinib - Dried Blood Spot Nilotinib

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON37855

Enrollment

Registered

2012-12-10

Start date

2013-02-04

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Myelogenous Leukemia

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients with CML who are treated with nilotinib.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Difference between specimens across blood sampling methods, and between duplicate specimens for the same blood sampling method will be determined.	—

Countries

Netherlands

Outcome results